Aug 1 (Reuters) - German Chemicals Group Evonik Industries Evkn.de on Thursday Said It Expected Its Core Profit for the Third Quarter to Be "on Par" With That of the Second Quarter.

The Speciality Chemicals Maker Said Its Second-Quarter Adjusted Earnings Before Interest, Tax, Depreciation and Amortisation (Ebitda) Was 578 Million Euros ($626 Million), in Line With the Preliminary Figure Published in July.

Evonik, Whose Chemicals Are Used in Products From Autos and Animal Feed to Pfizer and BioNTech's Covid Vaccine, Confirmed Its Annual Outlook for an Adjusted Ebitda of Between 1.9 Billion and 2.2 Billion Euros, Which It Raised Last Month.

The Outlook for Its Other Key Financial Figures Also Remains Unchanged, Evonik Added.

"We Are Headed in the Right Direction, and the Improvements in Our Key Financial Figures Compared to the Previous Year Are Really Encouraging," Chief Financial Officer Maike Schuh Said in a Statement.

"However, the Current Recovery Compares to a Very Weak 2023, and We Are Still a Long Way From Reaching Our Goals," Schuh Added.

The Company Said It Expected the Sale of Its Superabsorbents Business to Be Completed During the Third Quarter.

($1 = 0.9232 Euros)

(Reporting by Anastasiia Kozlova and Amir Orusov in Gdansk; Editing by Milla Nissi)

((Anastasiia.kozlova@Thomsonreuters.com; Amir.orusov@Thomsonreuters.com))